Jaktinib

DB17545InvestigationalSmall molecule

Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating...

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2, Tyrosine-protein kinase JAK1, and Janus (JAK) kinases
Curator reviewed
Also known as: Gecacitinib

Resolves to

Targets

O60674JAK2P23458JAK1

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Jaktinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account